Highest-materiality recent filing
Ardelyx Q2 revenue up 31% to $118.1M; cuts FY2026 IBSRELA guidance to $350-370M
Q2 total product revenue $118.1M (+31% YoY); IBSRELA $86.2M (+33%), XPHOZAH $31.9M (+27%).
Ardelyx draws $50M Term F Loan from SLR Investment Corp. for general corporate purposes
Received $50.0M Term F Loan on June 29, 2026, under existing loan agreement with SLR Investment Corp.
Ardelyx Q1 revenue $93.4M (+38% YoY); IBSRELA revenue $70.1M (+58% YoY)
Net loss $37.6M ($0.15/sh) vs $41.1M ($0.17/sh) Q1 2025; share-based comp $14.2M.
Ardelyx reports 2025 revenue $407.3M; IBSRELA up 73% to $274.2M; guides 2026 higher
IBSRELA revenue $274.2M in 2025 (+73% YoY); Q4 $86.6M (+61% YoY).
Ardelyx reports preliminary Q4 2025 IBSRELA sales ~$87M, XPHOZAH ~$28M; cash $265M
Preliminary unaudited U.S. net product sales: IBSRELA ~$87M Q4, ~$274M FY 2025.
Ardelyx Q3 2025: product revenue $105.5M, IBSRELA +92% YoY, guidance raised
Total Q3 product revenue $105.5M (+15% YoY); net loss $1.0M ($0.00 per share).
Ardelyx appoints Sue Hohenleitner as CFO
Appointed Sue Hohenleitner as CFO effective Nov 4, 2025; she joins Oct 13, 2025.
Ardelyx Q2 revenue $97.7M (+33%), raises IBSRELA guidance; CFO to depart
Q2 total revenue $97.7M (+33% YoY); IBSRELA net sales $65M (+84% YoY); XPHOZAH net sales $25M (-33% YoY).
Ardelyx draws $50M term loan, secures $100M additional capacity from SLR
Immediate draw of $50.0M (Term E Loan) under Fifth Amendment to 2022 Loan Agreement.
Ardelyx shareholders approve equity plan amendment increasing share reserve by 10M shares
Shareholders approved first amendment to 2014 equity plan, raising authorized shares from 58.5M to 68.5M.
Ardelyx reports Q1 2025 total revenue $74.1M (+61% YoY); IBSRELA $44.4M, XPHOZAH $23.4M
Total revenue $74.1M (+61% YoY); net loss $41.1M ($0.17 loss per share) vs $26.5M loss in Q1 2024.
Ardelyx reports FY2024 revenue $333.6M; narrows net loss to $39.1M; provides 2025 guidance
Total revenue $333.6M in 2024, up from $124.5M in 2023; driven by IBSRELA ($158.3M) and XPHOZAH ($160.9M) sales.
Ardelyx Q3 revenue $98.2M; IBSRELA $40.6M, XPHOZAH $51.5M; net loss $0.8M
IBSRELA Q3 net sales $40.6M (+15% QoQ); full-year guidance set at $145-150M.
Ardelyx Q2 total revenue $73.2M, driven by IBSRELA $35.4M and XPHOZAH $37.1M
IBSRELA Q2 net sales $35.4M, up ~25% QoQ; XPHOZAH Q2 net sales $37.1M, up from $15.2M in Q1 2024.
Ardelyx opts out of CMS TDAPA for XPHOZAH, foregoing add-on payment
Ardelyx will not apply to include XPHOZAH (tenapanor) in CMS ESRD PPS TDAPA program.
Ardelyx Q1 product revenue $45.6M (IBSRELA $28.4M, XPHOZAH $15.2M); net loss $26.5M
Q1 product-related revenue $45.6M: IBSRELA $28.4M (+149% YoY), XPHOZAH $15.2M (first full quarter after Oct 2023 approval).
Ardelyx reports FY2023 revenue $124.5M; IBSRELA sales $80.1M, guides 2024 $140-150M
IBSRELA net product sales $80.1M in FY2023, Q4 $28.1M (+26% QoQ); guides 2024 sales $140-150M.
Ardelyx reports preliminary Q4 2023 IBSRELA net sales of ~$28M, full year ~$80M, and XPHOZAH ~$2.5M
IBSRELA US net sales: Q4 ~$28M, FY2023 ~$80M (unaudited).
Ardelyx reports Q3 net income $6.6M; IBSRELA sales $22.3M; raises FY guidance to $76-78M
Q3 net income $6.6M ($0.03/share) vs net loss $22.9M in Q3 2022; total revenue $56.4M vs $5.0M.
Ardelyx announces FDA approval of XPHOZAH (tenapanor) for hyperphosphatemia in dialysis patients
FDA approved XPHOZAH to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy.
Ardelyx secures up to $100M additional debt; $50M committed Term C loan drawable by Mar 2024
Third Amendment adds $22.5M Term B loan (existing commitment) and $50M committed Term C loan drawable by March 15, 2024.
Ardelyx receives $30M milestone payments from Kyowa Kirin on Japan approval of tenapanor
Kyowa Kirin received MHLW approval in Japan for tenapanor for hyperphosphatemia in adult CKD patients on dialysis.
Ardelyx Q2 2023: IBSRELA rev $18.3M (+61% QoQ), net loss $17.1M, FY23 guidance $72-77M
IBSRELA net sales $18.3M in Q2 2023, up 61% QoQ from $11.4M in Q1.
Ardelyx FDA accepts XPHOZAH resubmission; PDUFA Oct 17, 2023
FDA accepted resubmission of NDA for XPHOZAH (tenapanor) for serum phosphate control in dialysis patients.
Ardelyx Q1 IBSRELA sales $11.4M, net loss $26.8M; XPHOZAH NDA resubmitted
IBSRELA net product sales $11.4M in Q1 2023, up from $0.5M in Q1 2022.
Net loss for FY2022 was $67.2M ($0.42/share) vs $158.2M ($1.52/share) in 2021.
Ardelyx receives FDA appeal grant for XPHOZAH; plans NDA resubmission in H1 2023
On Dec 27, 2022, FDA OND granted appeal of July 2021 CRL for XPHOZAH (tenapanor) after Nov 16 CRDAC favorable vote.
Ardelyx Q3 2022 net loss $22.9M; IBSRELA sales $4.9M; expects $35M Japan milestone
Net loss of $22.9M ($0.14 per share) versus $43.6M ($0.42) in Q3 2021; narrowed 47%.
Ardelyx shareholders reject reverse stock split; Nasdaq listing at risk
Reverse stock split proposal failed: 63.5M for (44% of outstanding), 33.4M against, insufficient to meet >50% threshold.
Ardelyx sells up to $20M in tenapanor Japan royalties to HealthCare Royalty
Up to $20M total: $10M upfront, $5M on Japan regulatory approval for hyperphosphatemia, $5M if net sales exceed target by end of 2025.
Ardelyx adjourns annual meeting on reverse stock split; needs more votes
Proposal to authorize reverse stock split (1:2 to 1:10) received 66.74% of votes cast but needs >50% of outstanding shares; meeting adjourned to July 13.
Ardelyx receives Nasdaq deficiency notice for minimum bid price; seeks reverse stock split approval
Nasdaq letter on May 23, 2022, for failure to maintain $1.00 minimum closing bid per share.
Ardelyx reports Q1 2022 net loss of $28.1M; first IBSRELA sales of $0.5M
First commercial sales of IBSRELA for IBS-C generated $0.5M in March 2022.
On April 28, 2025, the Company appointed Merdad Parsey, M.D., Ph.D, as a member of the Board of Directors (the “Board”) of Ardelyx, Inc., a Delaware corporation (the “Company”), effective immediately
The Company has appointed Joseph Reilly to replace Robert Felsch in his capacity as the Company’s Principal Accounting Officer effective November 15, 2024.
Mr. Felsch will remain with the Company and will transition to a senior financial advisor role within the Company
On November 13, 2023, Geoffrey A. Block, M.D. notified the Board of Directors (the “Board”) of Ardelyx, Inc. (the “Company”) of his decision to resign from the Board and the Nominating and Governance Committee of the Board, effective on November 13, 2023.
Effective upon Mr. Felsch’s appointment as Chief Accounting Officer, Justin Renz, the Company’s Chief Financial Officer, Principal Accounting Officer and Treasurer will no longer serve as Principal Accounting Officer, but will continue to serve as the Company’s Chief Financial Officer and Treasurer.
On March 10, 2022, Ardelyx, Inc. (the “Company”) appointed Robert Felsch as the Company’s Chief Accounting Officer.
Max materiality 0.85 · Median 0.70 · Most common event earnings